Author:
Heng Daniel Y. C.,Xie Wanling,Bjarnason Georg A.,Vaishampayan Ulka,Tan Min-Han,Knox Jennifer,Donskov Frede,Wood Lori,Kollmannsberger Christian,Rini Brian I.,Choueiri Toni K.
Reference18 articles.
1. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med.,2007
2. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma [abstract];Escudier;J Clin Oncol.,2007
3. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol. 2009;27(15S);Escudier;Abstract,5020
4. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206;Rini;J Clin Oncol.,2008
5. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial;Motzer;Lancet.,2008
Cited by
71 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献